Program stem-like CD8 T cells to enhance antiviral immunity against chronic viral infection

编程干细胞样 CD8 T 细胞以增强针对慢性病毒感染的抗病毒免疫力

基本信息

  • 批准号:
    10687970
  • 负责人:
  • 金额:
    $ 54.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-22 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Chronic infection by viruses such as HIV, HBV, and HCV remains a major global health challenge. During chronic viral infection, CD8 T cells fail to eradicate the virus and develop into a dysfunctional state, termed exhaustion. Exhausted CD8 T cells, which were first characterized in mouse model of chronic lymphocytic choriomeningitis virus (LCMV) infection, progressively lose effector function, upregulate inhibitory receptors, and exhibit dysregulated metabolism. Immunotherapies fail to completely reverse T-cell exhaustion or achieve sustained viral control during chronic viral infection. Thus, there is an unmet need to develop new strategies to overcome T-cell exhaustion and enhance the efficacy of immunotherapy against chronic viral infection. Although exhausted CD8 T cells were initially thought to be a homogeneous population, we and others have recently shown that a TCF1high antiviral CD8 T cell subset maintains long-term antiviral immunity through self-renewal and replenishing TCF1low terminally exhausted CD8 T cells during chronic viral infection. Importantly, these stem- like CD8 T cells are less exhausted and mediate the response induced by various immunotherapies. Our published studies have demonstrated stem-like CD8 T cells as a separate CD8 lineage with transcriptional and epigenetic programs that are distinct from those of terminally exhausted CD8 T cells and are tightly regulated by transcription factors, epigenetic regulators, and cytokines. The goal of this proposal is to define the molecular and cellular mechanisms regulating the immune response of stem-like CD8 T cells against chronic viral infection and evaluate strategies to improve antiviral immunity by targeting these pathways. Using chronic LCMV infection model, cutting-edge metabolic assay, multispectral quantitative imaging, and unique mouse genetic tools, we will identify the metabolic pathways and cell-cell interactions that endow stem-like CD8 T cells with their superior antiviral immunity and responsiveness to immunotherapies. These results will lay the foundation for the development of novel interventions to induce sustained control over chronic viral infections.
项目概要 HIV、HBV 和 HCV 等病毒的慢性感染仍然是全球主要的健康挑战。期间 慢性病毒感染时,CD8 T 细胞无法根除病毒并发展为功能失调状态,称为 精疲力尽。耗竭的 CD8 T 细胞,首次在慢性淋巴细胞性白血病小鼠模型中得到表征 脉络丛脑膜炎病毒 (LCMV) 感染,效应器功能逐渐丧失,抑制性受体上调, 表现出代谢失调。免疫疗法无法完全逆转 T 细胞耗竭或实现 慢性病毒感染期间持续的病毒控制。因此,制定新战略的需求尚未得到满足 克服T细胞耗竭并增强免疫疗法针对慢性病毒感染的功效。虽然 耗尽的 CD8 T 细胞最初被认为是同质群体,我们和其他人最近发现 研究表明,TCF1 高抗病毒 CD8 T 细胞亚群通过自我更新维持长期抗病毒免疫力 以及在慢性病毒感染期间补充 TCF1low 最终耗尽的 CD8 T 细胞。重要的是,这些干 CD8 T 细胞消耗较少,可介导各种免疫疗法诱导的反应。我们的 已发表的研究表明干细胞样 CD8 T 细胞是一个独立的 CD8 谱系,具有转录和 表观遗传程序与最终耗尽的 CD8 T 细胞不同,并且受到严格调控 转录因子、表观遗传调节因子和细胞因子。该提案的目标是定义分子 干细胞样CD8 T细胞对抗慢性病毒感染免疫反应的细胞机制调节 并评估通过针对这些途径来提高抗病毒免疫力的策略。使用慢性 LCMV 感染 模型、尖端代谢测定、多光谱定量成像和独特的小鼠遗传工具,我们 将确定代谢途径和细胞间相互作用,赋予干样 CD8 T 细胞优越的性能 抗病毒免疫力和对免疫疗法的反应。这些结果将为 开发新的干预措施以持续控制慢性病毒感染。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tuoqi Wu其他文献

Tuoqi Wu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tuoqi Wu', 18)}}的其他基金

Understand the molecular mechanism of age-associated decline in antiviral CD8 T cell immunity
了解与年龄相关的抗病毒 CD8 T 细胞免疫力下降的分子机制
  • 批准号:
    10726485
  • 财政年份:
    2023
  • 资助金额:
    $ 54.09万
  • 项目类别:
Program stem-like CD8 T cells to enhance antiviral immunity against chronic viral infection
编程干细胞样 CD8 T 细胞以增强针对慢性病毒感染的抗病毒免疫力
  • 批准号:
    10819055
  • 财政年份:
    2022
  • 资助金额:
    $ 54.09万
  • 项目类别:
Program stem-like CD8 T cells to enhance antiviral immunity against chronic viral infection
编程干细胞样 CD8 T 细胞以增强针对慢性病毒感染的抗病毒免疫力
  • 批准号:
    10365756
  • 财政年份:
    2022
  • 资助金额:
    $ 54.09万
  • 项目类别:
Rejuvenating aged T cell immunity by targeting stem cell-like CD8 T cells
通过靶向干细胞样 CD8 T 细胞恢复衰老 T 细胞免疫力
  • 批准号:
    10190752
  • 财政年份:
    2018
  • 资助金额:
    $ 54.09万
  • 项目类别:
Rejuvenating aged T cell immunity by targeting stem cell-like CD8 T cells
通过靶向干细胞样 CD8 T 细胞恢复衰老 T 细胞免疫力
  • 批准号:
    10516508
  • 财政年份:
    2018
  • 资助金额:
    $ 54.09万
  • 项目类别:
Rejuvenating aged T cell immunity by targeting stem cell-like CD8 T cells
通过靶向干细胞样 CD8 T 细胞恢复衰老 T 细胞免疫力
  • 批准号:
    10005996
  • 财政年份:
    2018
  • 资助金额:
    $ 54.09万
  • 项目类别:

相似海外基金

Effects of combining anti-CD40 and anti-CD11b mAb107 on survival of pig kidney xenografts in cynomolgus monkeys
抗CD40和抗CD11b mAb107联合使用对食蟹猴猪肾异种移植物存活的影响
  • 批准号:
    10425736
  • 财政年份:
    2022
  • 资助金额:
    $ 54.09万
  • 项目类别:
Effects of combining anti-CD40 and anti-CD11b mAb107 on survival of pig kidney xenografts in cynomolgus monkeys
抗CD40和抗CD11b mAb107联合使用对食蟹猴猪肾异种移植物存活的影响
  • 批准号:
    10618872
  • 财政年份:
    2022
  • 资助金额:
    $ 54.09万
  • 项目类别:
Control of Human NKT cell Responses by Immunoregulatory Liposomes and Anti- CD40 Antibody
通过免疫调节脂质体和抗 CD40 抗体控制人 NKT 细胞反应
  • 批准号:
    15K20115
  • 财政年份:
    2015
  • 资助金额:
    $ 54.09万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Creation of an Anti-CD40 Superagonistic Monoclonal Antibody
抗 CD40 超激动单克隆抗体的创建
  • 批准号:
    7672854
  • 财政年份:
    2009
  • 资助金额:
    $ 54.09万
  • 项目类别:
Preparation of activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody
使用青霉素灭活的化脓性链球菌 (OK432) 和抗 CD40 抗体制备能够在转移性癌症患者中启动肿瘤特异性细胞毒性 T 淋巴细胞的活化树突状细胞
  • 批准号:
    17591475
  • 财政年份:
    2005
  • 资助金额:
    $ 54.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ANTI-CD40 ANTIBODY IMMUNOTHERAPY IN SIV I INFECTION
SIV I 感染的抗 CD40 抗体免疫治疗
  • 批准号:
    6970822
  • 财政年份:
    2004
  • 资助金额:
    $ 54.09万
  • 项目类别:
Antitumor Mechanisms of anti-CD40/CpG-activated Macrophages
抗CD40/CpG激活巨噬细胞的抗肿瘤机制
  • 批准号:
    8306229
  • 财政年份:
    2002
  • 资助金额:
    $ 54.09万
  • 项目类别:
Antitumor Mechanisms of anti-CD40/CpG-activated Macrophages
抗CD40/CpG激活巨噬细胞的抗肿瘤机制
  • 批准号:
    7522880
  • 财政年份:
    2002
  • 资助金额:
    $ 54.09万
  • 项目类别:
Antitumor Mechanisms of anti-CD40/CpG-activated Macrophages
抗CD40/CpG激活巨噬细胞的抗肿瘤机制
  • 批准号:
    8117797
  • 财政年份:
    2002
  • 资助金额:
    $ 54.09万
  • 项目类别:
Antitumor Mechanisms of anti-CD40/CpG-activated Macrophages
抗CD40/CpG激活巨噬细胞的抗肿瘤机制
  • 批准号:
    7886648
  • 财政年份:
    2002
  • 资助金额:
    $ 54.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了